18F-PSMA 1007 in Suspected Renal Cell Carcinoma

Area of Science:

• Nuclear Medicine
• Oncology
• Radiochemistry

Background:

• Renal cell carcinoma (RCC) diagnosis and staging are critical for treatment planning.
• Fluorodeoxyglucose (F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) is used in oncology but has limitations for certain tumor types.
• Prostate-specific membrane antigen (PSMA) PET/CT is emerging as a valuable tool in cancer imaging.

Observation:

• A 60-year-old male with suspected right RCC underwent both F-FDG PET/CT and Fluorine-18 (F)-PSMA 1007 PET/CT.
• F-PSMA 1007 PET/CT demonstrated intense tracer uptake in the primary right kidney tumor and all lung nodules.
• This intense uptake in the primary renal tumor with F-PSMA 1007 contrasts with findings from some previous pilot studies using Gallium-68 (Ga)-PSMA.

Findings:

• F-PSMA 1007 PET/CT revealed significant tracer avidity in the primary RCC.
• Consistent and intense tracer accumulation was observed in metastatic lung nodules.
• The primary renal tumor itself showed notable tracer concentration with F-PSMA 1007, differing from some prior Ga-PSMA studies.

Implications:

• F-PSMA 1007 PET/CT may offer enhanced preoperative insights into the etiology and histopathological characteristics of suspected RCC.
• This imaging modality could improve tumor staging accuracy for renal masses.
• F-PSMA 1007 PET/CT holds potential for theranostic applications in the management of renal cell carcinoma.